Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | GSK3B | P49841 | 2/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylamine SCHEMBL28118187 | 0.93 | KMT2A (0.50) | TDP1MAPK1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL20221553 | 0.83 | MAPT (0.44) | MAPK1MAPTHPGDSMN1; SMN2KDM4E | |
| SCHEMBL5854018 | 0.82 | NPC1 (0.50) | TDP1MAPK1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL5245553 | 0.82 | MAPT (0.50) | TDP1MAPK1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL17702639 | 0.80 | NPC1 (0.53) | TDP1MAPK1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL5540670 | 0.80 | TDP1 (0.53) | TDP1MAPK1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL10465723 | 0.80 | GSK3B (0.53) | MAPTHPGDKDM4EMEN1CYP3A4 | |
| SCHEMBL11074838 | 0.80 | GSK3B (0.53) | MAPTHPGDSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL31472280 | 0.79 | NPC1 (0.47) | TDP1MAPK1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL9277424 | 0.79 | NPC1 (0.47) | TDP1MAPK1MAPTHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 747 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122037808-A | Adhesive tape | 长兴材料工业股份有限公司 | 2026-05-15 | — | — | CN | claimed |
| JP-2007501805-A | — | — | 2007-02-01 | — | — | JP | claimed |
| US-7144700-B1 | Photolithographic solid-phase polymer synthesis | AFFYMETRIX, INC. (US) | 2006-12-05 | — | — | US | claimed |
| EP-1651638-A1 | PYRIDYL PIPERAZINYL UREAS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-03 | — | — | EP | claimed |
| US-6888001-B2 | Selective modulators of the nicotinic acetylcholine receptor useful in the treatment of pain, Alzheimer's disease, memory loss or dementia or loss of motor function. | LEE JUNG S (US) | 2005-05-03 | — | — | US | claimed |
| US-20050049241-A1 | Pyridyl piperazinyl ureas | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-03 | — | — | US | claimed |
| WO-2005014580-A1 | PYRIDYL PIPERAZINYL UREAS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-17 | — | — | WO | claimed |
| EP-1107965-B1 | PYRIDYL ETHERS AND THIOETHERS AS LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTOR AND ITS THERAPEUTIC APPLICATION | ORTHO MCNEIL PHARM INC (US) | 2004-08-11 | — | — | EP | claimed |
| US-20030207858-A1 | Selective modulators of the nicotinic acetylcholine receptor useful in the treatment of pain, Alzheimer's disease, memory loss or dementia or loss of motor function. | LEE JUNG S (US) | 2003-11-06 | — | — | US | claimed |
| US-6562847-B1 | Useful in the treatment of pain, Alzheimer's disease, memory loss or dementia or loss of motor function | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-05-13 | — | — | US | claimed |
| US-4181800-A | ANTIBIOTICS FROM SUBSTITUTED PERHYDRO-S-TRIAZINES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-01-01 | — | — | US | claimed |
| US-4180571-A | Arylmalonamido-1-oxadethiacephalosporins | SHIONOGI & CO., LTD. (JP) | 1979-12-25 | — | — | US | claimed |
| US-4162251-A | Process for the preparation of β-lactam compounds | SANKYO COMPANY LIMITED (JP) | 1979-07-24 | — | — | US | claimed |
| US-4138486-A | BACTERICIDES | SHIONOGI & CO., LTD. (JP) | 1979-02-06 | — | — | US | claimed |
| US-4064122-A | Hydroxy-substituted cephalosporins | ISHIMARU TOSHIYASU | 1977-12-20 | — | — | US | claimed |
| US-4053286-A | ACYLATION | MERCK & CO., INC. (US) | 1977-10-11 | — | — | US | claimed |
| US-4024249-A | FOR COMBATTING MICROORGANISMS | CIBA-GEIGY CORPORATION (US) | 1977-05-17 | — | — | US | claimed |
| US-4017488-A | Process for preparing 7β-acylamino-7α-alkoxycephalosporins | SANKYO COMPANY LIMITED (JA) | 1977-04-12 | — | — | US | claimed |
| US-4014873-A | Process for the production of 7-acylamidocephalosporins | MERCK & CO., INC. (US) | 1977-03-29 | — | — | US | claimed |
| US-4012380-A | 7-Acylamino-3-acyl-2(or 3)cephems | ELI LILLY AND COMPANY (US) | 1977-03-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049241-A1 | Pyridyl piperazinyl ureas | VIPR1, UTS2R, GPR17 | TDP1 3242/4885MAPK1 851/4885MAPT 4162/4885 |
| US-20030207858-A1 | Selective modulators of the nicotinic acetylcholine receptor useful in the treatment of pain, Alzheimer's disease, memory loss or dementia or loss of motor function. | CHRM1, CHRM5, CHRM2 | TDP1 670/4885MAPK1 858/4885MAPT 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.